Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability ...
Sep 13, 2012
0
0
Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic ...
May 31, 2017
0
0
A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy—a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable ...
Jun 12, 2024
0
14
Aire expression in the thymus contributes to immune tolerance by eliminating auto-reactive T cells; insufficient elimination causes autoimmune disorders. The Aire gene was thought to be expressed only in the thymus, but recently, ...
Apr 11, 2019
0
2
Immune checkpoint therapy has revolutionized cancer therapy, leading to long-term remission for patients with advanced cancer. However, most cancer patients either do not respond or have only short-term responses to checkpoint ...
Jun 24, 2019
0
0
Researchers at Dana-Farber Cancer Institute, in collaboration with colleagues from Memorial Sloan Kettering Cancer Center in New York (Dr. Kai Rejeski) and the LMU Hospital in Munich, Germany (Dr. Tobias Tix), have found ...
Jul 8, 2024
0
6
Researchers at Children's Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC). The ...
Jun 14, 2024
0
53
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, ...
Jan 23, 2023
0
4
A new technology for cellular immunotherapy developed by Abramson Cancer Center researchers at Penn Medicine showed promising anti-tumor activity in the lab against hard-to-treat cancers driven by the once-considered 'undruggable' ...
Jul 26, 2021
0
188
Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer ...
Aug 30, 2022
0
42
